Biosimilars balance reduced cost against nonmedical-switching fear

Two days of discussions in mid-July at a Food and Drug Administration Advisory Committee meeting that judged the merits of two biosimilar agents undergoing agency review highlighted the intrinsic tension at the heart of biosimilar drug development. The promise and appeal of these new agents – the...
Source: Skin and Allergy News - Category: Dermatology Source Type: news